Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Senior H1 adjusted operating profits up 10pc

(Sharecast News) - High technology components and systems manufacturer Senior's interim results came in broadly in line with expectations on Monday, with the group underlining progress on its transformation into a focused fluid conveyance and thermal management business. Senior said revenue from continuing operations rose 5% to £371.2m, driven by growth in aerospace and flexonics, while adjusted operating profit climbed 10% to £31.2m, with margins improving by 60 basis points to 8.4%.

The FTSE 250-listed firm said its aerospace division saw a 7% revenue uplift, supported by stronger defence volumes and semiconductor demand, while flexonics benefited from new contracts in land vehicles and downstream oil and gas. Basic earnings per share increased 34% to 5.07p, and free cash flow jumped 43% to £10.6m.

Senior hiked its interim dividend by 13% to 0.85p and reaffirmed its FY outlook. It also stated that funds from the £200m planned sale of its aerostructures unit would be used to reduce its net debt position and fund a £40m share buyback.

Chief executive David Squires said: "Senior has delivered a strong set of results in H1 2025 in line with our expectations.

"Looking ahead, we are delivering on our strategy which gives us confidence in our ability to achieve our medium-term financial targets."

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.